A- A A+

USA. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder - 2020 Focused Update

The ASAM National Practice Guideline 2020 focused update is intended to inform and empower clinicians, health system administrators, criminal justice system administrators, and policymakers who are interested in implementing evidence-based practices to improve outcomes for individuals with OUD. This is especially critical in the context of the ongoing COVID-19 emergency, which threatens to curtail patient access to evidence-based treatment.  

The document is an update to the previous NPG released in 2015 and includes major revisions to 35 existing recommendations, along with the addition of 13 new recommendations. 

This focused update was developed over the course of 14 months with consensus from an independent committee of experts and the use of a rigorous RAND/RAM methodology facilitated by researchers from Research Triangle Institute (RTI). (ASAM – American Society of Addiction Medicine)

https://www.asam.org/Quality-Science/quality/2020-national-practice-guideline

The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management

This clinical guideline provides the latest information to provide guidance on the identification and management of alcohol withdrawal in patients with varying degrees of syndrome severity. It is especially critical in the context of the ongoing COVID-19 emergency, which threatens to curtail patient access to evidence-based treatment.

https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf

UK. Guidance: Opioid substitution treatment: guide for keyworkers 

Advice for drug treatment and recovery workers to help them to deliver safe and effective OST to service users. (PHE – Public Health England, 21.07.2021)

https://www.gov.uk/government/publications/opioid-substitution-treatment-guide-for-keyworkers

UK. Guidance. Opioid substitution treatment: service self-assessment tool 

Self-assessment tool, good-practice examples and resources for community drug treatment services to help them deliver OST in line with clinical guidance. (PHE – Public Health England, 21.07.2021)

https://www.gov.uk/government/publications/opioid-substitution-treatment-service-self-assessment-tool

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. 

Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, Nelson L, Schwarz E, Shahid S, Stader D, Wilson MP, D'Onofrio G. 

Ann Emerg Med. 2021 Jun 22:S0196-0644(21)00306-1. doi: 10.1016/j.annemergmed.2021.04.023. Epub ahead of print. PMID: 34172303.

https://www.annemergmed.com/article/S0196-0644(21)00306-1/fulltext

Interobserver agreement between emergency clinicians and nurses for Clinical Opiate Withdrawal Scale. 

Tomaszewski CA, Quenzer F, Corbett B, Lafree A, Lasoff D, Romo J, Mukau L. 

J Am Coll Emerg Physicians Open. 2021 Jun 18;2(3):e12462. doi: 10.1002/emp2.12462. PMID: 34179884; PMCID: PMC8212561.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212561/

Addiction Medicine Practice-Based Research Network (AMNet): Assessment Tools and Quality Measures. 

Clarke DE, Ibrahim A, Doty B, Patel S, Gibson D, Pagano A, Thompson L, Goldstein AB, Vocci F, Schwartz RP. 

Subst Abuse Rehabil. 2021 Jun 25;12:27-39. doi: 10.2147/SAR.S305972. PMID: 34211312; PMCID: PMC8240849.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240849/

Schottland. MAT Standards Informed Response for Benzodiazepine Harm Reduction 

Call to action The unprecedented harm associated with street benzodiazepines in Scotland is a public health emergency that demands a different approach. The false notion that postponing change in prescribing practice is the safest position and the current status quo,is unacceptable. The current rate of high levels of benzodiazepine related harm seen in Scotland qualify in the Orange Guidelinesas ‘exceptional circumstances’. We all have a responsibility to listento, assess and understand a person’s unique story of benzodiazepineuse to identify appropriate treatment and care. Initial conversations should address immediate risk of harm, particularly overdose and death. Conversations should be underpinned by principles of psychological and trauma informed care including safety, empowerment, choice, collaboration and trust, in line with the MAT standards (Appendix A). (SDF – Scottish Draugs Forum, Juki 2021)

http://www.sdf.org.uk/wp-content/uploads/2021/06/MAT-Standards-Informed-Response-for-Benozdiazepine-Harm-Reduction_interim-guidance_June21.pdf

Kanada. Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. 

Centre for Addiction and Mental Health. Canada. Published May 2021. 

https://www.camh.ca/-/media/files/professionals/canadian-opioid-use-disorder-guideline2021-pdf.pdf

SAMHSA. Telehealth for the Treatment of Serious Mental Illness and Substance Use Disorders

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.

SAMHSA – Substance Abuse and Mental Health Services Administration, USA, Publication ID PEP21-06-02-001, Publication Date: June 2021 

https://store.samhsa.gov/product/telehealth-for-treatment-serious-mental-illness-substance-use-disorders/PEP21-06-02-001

International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. 

Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens ASA, van de Glind G, Banaschewski T, Barta C, Begeman A, Casas M, Crunelle CL, Daigre Blanco C, Dalsgaard S, Demetrovics Z, den Boer J, Dom G, Eapen V, Faraone SV, Franck J, González RA, Grau-López L, Groenman AP, Hemphälä M, Icick R, Johnson B, Kaess M, Kapitány-Fövény M, Kasinathan JG, Kaye SS, Kiefer F, Konstenius M, Levin FR, Luderer M, Martinotti G, Matthys FIA, Meszaros G, Moggi F, Munasur-Naidoo AP, Post M, Rabinovitz S, Ramos-Quiroga JA, Sala R, Shafi A, Slobodin O, Staal WG, Thomasius R, Truter I, van Kernebeek MW, Velez-Pastrana MC, Vollstädt-Klein S, Vorspan F, Young JT, Yule A, van den Brink W, Hendriks V. 

Eur Addict Res. 2020;26(4-5):223-232. doi: 10.1159/000508385. Epub 2020 Jul 7. PMID: 32634814.

https://www.karger.com/Article/FullText/508385

Schottland. Drug Medication Assisted Treatment (MAT) standards: access, choice, support

Evidence based standards to enable the consistent delivery of safe, accessible, high-quality drug treatment across Scotland. These are relevant to people and families accessing or in need of services, and health and social care staff responsible for delivery of recovery oriented systems of care. (Scottish Government, Population Health Directorate, 31.05.2021)

https://www.gov.scot/publications/medication-assisted-treatment-mat-standards-scotland-access-choice-support/

Guidelines for Partnering with People with Lived and Living Experience of Substance Use and Their Families and Friends 

Canadian Centre on Substance Use and Addiction, 2021

https://ccsa.ca/sites/default/files/2021-04/CCSA-Partnering-with-People-Lived-Living-Experience-Substance-Use-Guide-en.pdf

USA. Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder

SUMMARY:

The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder provides eligible physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives, who are state licensed and registered by the DEA to prescribe controlled substances, an exemption from certain statutory certification requirements related to training, counseling and other ancillary services (i.e., psychosocial services).

(Office of the Secretary, Department of Health and Human Services, USA, 28.04.2021)

https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder

USA. HHS Releases New Buprenorphine Practice Guidelines, Expanding Access to Treatment for Opioid Use Disorder

In an effort to get evidenced-based treatment to more Americans with opioid use disorder, the Department of Health and Human Services (HHS) is releasing new buprenorphine practice guidelines that among other things, remove a longtime requirement tied to training, which some practitioners have cited as a barrier to treating more people. (SAMHSA – Substance Abuse and Mental Health Services Administration, USA, 27.04.2021)

https://www.samhsa.gov/newsroom/press-announcements/202104270930

Handbook for Healthcare Executives - Creating a Culture of Safety for Opioid Prescribing

Healthcare executives have an important role in creating a culture for safer opioid prescribing. This handbook contains insights and advice from healthcare executives and quality improvement leaders from four different health systems representing urban, suburban and rural settings. They share their experiences engaging internal and external stakeholders, working across interdisciplinary teams, leveraging data to inform efforts, implementing training and educational efforts, and much more. (CDC – Centers for Disease Control und Prevention, Mai 2021)

https://www.cdc.gov/drugoverdose/prescribing/executive-handbook.html

Clinical Practice Guideline on Pharmacological and Psychological management of adult patients with Schizophrenia Spectrum Disorders and a comorbid substance use. 

Arranz B, Garriga M, Bernardo M, Gonzalez-Pinto A, Arrojo M, Torrens M, Tirado-Muñoz J, Fonseca F, Saiz PA, Florez G, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, Lopez A, San L. 

Adicciones. 2021 Mar 11;0(0):1504. English, Spanish. doi: 10.20882/adicciones.1504. Epub ahead of print. PMID: 33768260.

https://www.adicciones.es/index.php/adicciones/article/view/1504

Clinical practice guideline on pharmacological and psychological management of adult patients with depression and a comorbid substance use disorder. 

Torrens M, Tirado-Muñoz J, Fonseca F, Farré M, Gonzalez-Pinto A, Arrojo M, Bernardo M, Arranz B, Garriga M, Saiz PA, Florez G, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, Lopez A, San L. 

Adicciones. 2021 Mar 12;0(0):1559. English, Spanish. doi: 10.20882/adicciones.1559. Epub ahead of print. PMID: 33768269.

https://www.adicciones.es/index.php/adicciones/article/view/1559

Schottland. Medication Assisted Treatment - MAT Standards for Scotland - Access, Choice, Support

Scottish Drugs Deaths Task Force, Interim report On behalf of the MAT Subgroup, March 2021, 

Report prepared by Elinor Dickie, Tracey Clusker, Duncan McCormick, with special thanks to Lindsey Murphy, Austin Smith, Liz Taylor,Karen Mailer& Sara Hafiz

http://www.sdf.org.uk/wp-content/uploads/2021/03/MAT-Subgroup-Interim-Report-on-programme-to-date_Mar21.pdf

UK. Guidance: Injectable opioid treatment: commissioning and providing services 

Guidance on commissioning and providing injectable opioid treatment for people with opioid dependence who have not responded to oral treatment. (Government UK, Public Health England, 19.03.2021)

https://www.gov.uk/government/publications/injectable-opioid-treatment-commissioning-and-providing-services

Canadian national consensus guidelines for naloxone prescribing by pharmacists. 

Tsuyuki RT, Arora V, Barnes M, Beazely MA, Boivin M, Christofides A, Patel H, Laroche J, Sihota A, So R. 

Can Pharm J (Ott). 2020 Aug 26;153(6):347-351. doi: 10.1177/1715163520949973. PMID: 33282024; PMCID: PMC7689616.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689616/

USA. Use of Medication-Assisted Treatment in Emergency Departments

This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation. (Substance Abuse and Mental Health Administration (SAMHSA), USA, 05.02.2021)

https://www.samhsa.gov/resource/ebp/use-medication-assisted-treatment-emergency-departments

We're in this together - All about treatment for opioid dependence from people who have lived it - Client guide

(European Network of People who Use Drugs (EuroNPUD), 30.01.2021)

http://fileserver.idpc.net/library/EuroNPUD-OST-Client-Guide-Int-English.pdf

The Chinese version of obsessive compulsive drug use scale: validation in outpatient methadone maintenance treatment program. 

Gong H, Zhang Y, Ren Q, Zhou Z, Zhou H, Sun X, Zhang C, Voon V, Zhao M, Yu S. 

BMC Psychiatry. 2020 Sep 25;20(1):465. doi: 10.1186/s12888-020-02843-2. PMID: 32977774; PMCID: PMC7517618.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517618/

The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder - 2020 Focused Update

The ASAM National Practice Guideline 2020 focused update is intended to inform and empower clinicians, health system administrators, criminal justice system administrators, and policymakers who are interested in implementing evidence-based practices to improve outcomes for individuals with OUD. This is especially critical in the context of the ongoing COVID-19 emergency, which threatens to curtail patient access to evidence-based treatment.  

The document is an update to the previous NPG released in 2015 and includes major revisions to 35 existing recommendations, along with the addition of 13 new recommendations.

This focused update was developed over the course of 14 months with consensus from an independent committee of experts and the use of a rigorous RAND/RAM methodology facilitated by researchers from Research Triangle Institute (RTI).

https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf

EMCDDA operating guidelines for the risk assessment of new psychoactive substances

Summary

The purpose of these guidelines is to ensure compliance with the scope and requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) in respect to the risk assessment procedure for and reporting on new psychoactive substances.

To operationalise the technical aspects of the risk assessment, the guidelines are supported by a set of Guidance notes developed by the EMCDDA. The Guidance notes will be adapted as required in order to reflect developments in the field of new psychoactive substances and risk assessment. (EMCDDA, Lissabon, Dezember 2020)

https://www.emcdda.europa.eu/system/files/publications/13482/Risk%20Assessment%20guidelines.pdf

Schottland. Standards for Scotland: Access - Choice – Support -- Consultation on the standards&implementation

Medication Assisted Treatment (MAT), Schottland, November 2020

https://drugdeathstaskforce.scot/media/1164/sddt-mat-standards_for-consultation_nov2020.pdf

Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders

This guide reviews interventions for people living with substance use and mental disorders who are at risk for or living with HIV. Selected interventions are in alignment with goals of the federal “Ending the HIV Epidemic: A Plan for America” (EHE) initiative.

SAMHSA – Substance Abuse and Mental Health Services Administration, Rockville, USA

Publication ID PEP20-06-03-001, Publication Date November 2020

https://store.samhsa.gov/product/Prevention-and-Treatment-of-HIV-Among-People-Living-with-Substance-Use-and-or-Mental-Disorders/PEP20-06-03-001

Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians. 

Abraham GM, Obley AJ, Humphrey LL, Qaseem A. World 

Ann Intern Med. 2020 Oct 6. doi: 10.7326/M19-3860. Epub ahead of print. PMID: 33017566.

https://www.acpjournals.org/doi/10.7326/M19-3860

Effects of the new prescribing standards in British Columbia on consumption of opioids and benzodiazepines and z drugs. 

Crabtree A, Rose C, Chong M, Smolina K. 

Can Fam Physician. 2019;65(5):e231-e237.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516682/